New hope for tough leukemia: experimental drug debio 1562M enters human trials

NCT ID NCT06969430

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 19 times

Summary

This study tests a new drug called Debio 1562M for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The trial has two phases: first, to find a safe dose, and second, to see if the drug can shrink or control the cancer. About 134 participants will take part in this early-stage research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope Comprehensive Cancer Center

    RECRUITING

    Duarte, California, 91010, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Moffitt Cancer Center and Research Institute Hospital

    RECRUITING

    Tampa, Florida, 33612-9416, United States

  • Roswell Park Comprehensive Cancer Center

    RECRUITING

    Buffalo, New York, 14203, United States

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • The Ohio Sate University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

Conditions

Explore the condition pages connected to this study.